Stock Taper 
NeurAxis, Inc., founded in 2011 and based in Carmel, Indiana, develops neuromodulation devices like IB-Stim for treating functional abdominal pain in patients aged 11-18, primarily serving hospitals and clinics.
IB-Stim is an FDA-cleared non-invasive neuromodulation device that uses percutaneous electrical nerve field stimulation behind the ear to treat IBS-related abdominal pain and dyspepsia in both children and adults.
NeurAxis announced that a major national health insurer has established medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. This decision adds approximately 45 million covered lives and increases the total national coverage for PENFS to around 100 million, significantly expanding patient access to the company's IB-Stim device ahead of a new Category I CPT code taking effect on January 1, 2026.
NeurAxis (NASDAQ: NRXS - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 11.8% of NeurAxis shares are held
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 NERV | $3.33 | COMPARE |
 RLYB | $16.98 | COMPARE |
 TAOX | $3.65 | COMPARE |
 XCUR | $1.05 | COMPARE |
 NRSN | $3.65 | COMPARE |
 ENLV | $0.36 | COMPARE |
 CLGN | $3.53 | COMPARE |
 CVKD | $0.92 | COMPARE |
